Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIPAC-003 dose-optimization lead-in with eftilagimod alpha plus paclitaxel in HER2-negative/low metastatic breast cancer
2022-003323-17Phase 2Active
- Sponsor
- Immutep Limited
- Start
- Jan 2023
- Modality
- Vaccines & Immunotherapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eftilagimod alpha in breast cancer, sponsored by Immutep Limited. Primary endpoint: Dose optimization endpoints. Started Jan 2023; status: active.
02
Drugs
eftilagimod alpha
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2022-003323-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003323-17.